Zimmer Biomet Announces Preliminary Senior Notes Offering

Overview

On November 5, 2026, Zimmer Biomet Holdings, Inc. filed a preliminary prospectus supplement (Form 424B5) under Registration Statement No. 333-285227 for an offering of USD-denominated senior unsecured notes. Simultaneously, the company announced a concurrent offering of Euro-denominated senior notes via a separate prospectus supplement.

Offering Structure & Terms

• Issuer: Zimmer Biomet Holdings, Inc.
• Security: Senior Notes (unsecured, unsubordinated)
• Ranking: Ranks equally in right of payment with all existing and future unsecured and unsubordinated obligations; structurally junior to subsidiary liabilities.
• Denominations: Minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.
• Joint Book-Running Managers: Barclays, BofA Securities, J.P. Morgan, Mizuho, and SMBC Nikko.
• Concurrent Offering: Euro-denominated notes offering announced concurrently; neither offering is conditioned upon the completion of the other.

Use of Proceeds

Net proceeds from this offering, together with the concurrent Euro notes offering (if completed), are intended for general corporate purposes. These may include:

• Repayment or refinancing of upcoming maturities (such as existing 2026 and 2027 senior notes)
• Share repurchases
• Capital commitments
• Potential acquisitions

Capitalization & Financial Context

As of September 30, 2026, Zimmer Biomet reported approximately $7.5 billion in total consolidated indebtedness, with zero debt held at the operating subsidiary level.